Evotec SE

Ladies and gentlemen, welcome to the Evotech SA Quarterly Statement 9 Month 2024 and Capital Market Briefing Conference Call. I am Sergin, the Chorus Call Operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Volker Braun. Please go ahead.

Thank you, Sertian, and a warm welcome to all of you following our webcast today. We will cover nine months' results, and we will provide an update on the progress we have made, both operational and also strategic. Before handing over to Christian and Leticia, it is my duty to point to the disclaimer and the cautionary note regarding forward-looking statements, which you find on slide two of the deck that we share today. Moreover, while we reserved sufficient time for you to place all the questions you may have, please allow me to mention that this call will hardly be longer than two hours. And it's now my pleasure to hand over to Christian, who will guide you through today's agenda.

Good morning, good afternoon. Thank you for taking the time to dial in today. Before we go into content, let me tell you how we will approach this call. Slightly different from previous earnings calls, this will be an extended capital market briefing, so the Q3 results are only a small part of what I want to cover. I will speak about where I was able to extend today and about the ongoing initiatives and parties to prepare for the future. It's very clear that 2024 has been a pivotal year for Evotech. We have experienced a lot of change and challenges. Now, my job is to rebuild the trust and to outline a compelling direction for the future, rather than to spend too much time looking backwards. My ambition is to provide clarity, a transparent approach, and reliability. Consider this call as the starting point for taking you along the journey ahead of us. So, we have a lot to cover today, but before diving into the details, I want to set the tone. The tone not only for today's presentation, but also for future direction. What can you expect from me during my tenure? It's simply to say, and it takes a lot to execute, it's uncompromising excellence. Evotech's work has never been more crucial. Unmet medical needs continue to increase. New treatments are needed to tackle serious diseases. Drug discovery and development costs are constantly on the rise. Our partners rely on us our scientists and our technology to develop the future medicines that matter through redefining R&D, delivering faster and better outcome and raising the likelihood of success.